Need to keep on high of the science and politics driving biotech immediately? Join to get our biotech e-newsletter in your inbox.
Morning. Right now, we focus on conflicts of curiosity within the newly appointed ACIP group, are unhappy to listen to of a second loss of life from Sarepta’s gene remedy for Duchenne muscular dystrophy, and see Anne Wojcicki win again 23andMe.
The necessity-to-know this morning
- Supernus Prescription drugs mentioned it’s buying Sage Therapeutics, the distressed maker of a drug for postpartum melancholy, for $561 million. Final January, Sage rebuffed a $469 million takeover supply from Biogen, which co-markets the postpartum melancholy tablet, known as Zurzuvae.
Second loss of life tied to Sarepta’s Duchenne remedy
Sarepta Therapeutics has suspended shipments of its Duchenne muscular dystrophy gene remedy, Elevidys, to non-ambulatory sufferers after a second loss of life from acute liver failure. This is similar aspect impact that was seen within the first deadly case disclosed this previous March. Each sufferers have been boys who had misplaced the flexibility to stroll, STAT’s Andrew Joseph writes — a stage of illness development widespread in adolescence.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
